Kala Pharmaceuticals receives Nasdaq approval to transfer listing to Capital Market

KALA BIO, Inc.

Transfer from Nasdaq Global Select to Capital Market approved, effective Jan 11, 2023.
Company met minimum stockholders' equity requirement (Rule 5550(b)(1)) and market value of publicly held shares (Rule 5550(a)(5)).
Common stock continues trading under ticker KALA on the Nasdaq Capital Market.
Listing transfer does not affect corporate governance requirements or continuous trading nature.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.